Indivior Plc

Indivior Plc

INDV

Market Cap$2.89B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Indivior PlcIndivior Plc-10.3-1%1.4-0.2
$13.00

Target Price by Analysts

18.4% upsideIndivior Plc Target Price DetailsTarget Price
$-8.12

Current Fair Value

174% downside

Overvalued by 174% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.89 Billion
Enterprise Value$2.59 Billion
Dividend Yield$0 (0%)
Earnings per Share$0.01
Beta0.2
Outstanding Shares134,848,000

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-10.31
PEG10
Price to Sales1.37
Price to Book Ratio-3.66
Enterprise Value to Revenue2.18
Enterprise Value to EBIT14.21
Enterprise Value to Net Income-1169
Total Debt to Enterprise0.03
Debt to Equity-0.25

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Indivior Plc

CEO: Shaun Thaxter

Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...